Skip to content

The Metabolism research of KLK treating acute cerebral Ischemic Stroke: focus on drug Frequency–Efficacy relationship

The Metabolism research of KLK treating acute cerebral Ischemic Stroke: focus on drug Frequency–Efficacy relationship

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPD-16008508
Enrollment
Unknown
Registered
2016-05-20
Start date
2016-06-30
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cerebral infarction

Interventions

Treatment group:Inject the drug three times a day,for 14 days
Control group:Inject the drug Once a day, for 14 days

Sponsors

The General Hospital of Shenyang Military
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Age 18 to 80 years old 2.First time diagnosed or have history of acute anterior circulation cerebral infarction without serious; sequelae (mRS=0-2); 3.Acute anterior circulation cerebral infarction diagnosed <=48h; 4.Atherosclerotic Stenosis of the Middle Cerebral Artery; 5.7=NIHSS = 22; 6.Have provided singed written informed consent.

Exclusion criteria

Exclusion criteria: 1. Cerebal CT shows cerebal hemorrhage disease: cerebal hemorrhage, subarachnoid hemorrhage, etc.; 2. Transient ischemic attack; 3. Serious disturbance of onsciousness: Glasgow Coma ScaleGCS(GCS) 1.5 or APTT > 2 times; 7. Abnormal liver function (ALT/AST > 1.5 x ULN), abnormal renal function (Cr > normal level ); 8.Have seizures or other serious systemic diseases that investigator determined should not enter this research; 9. The investigator determined for cardiac stroke or a heart of source sex stroke risk factors (such as atrial fibrillation, echocardiography found mural thrombus, cardiomyopathy, etc.); 10. The patient diagnosis with any malignant tumor that 5 years prior to the start of the study (except basal cell carcinoma); 11. Severe dementia or the investigator estimated the person can't cooperate to assess; 12. With severe hypertension failed to control: systolic blood pressure 200 mmHg or diastolic blood pressure 110 mmHg; Low blood pressure, systolic blood pressure < 90 mmHg and/or diastolic blood pressure < 60 mmHg; 13. Allergic to human urinary kallikrein; 14. During pregnancy, lactation or Have Plan to pregnancy patients; 15. Allergic to contrast agent; 16. In other clinical subjects in the 3 months; 17. The investigator in consideration of the other condition that the patients doesn't fit to participate in this clinical study.

Design outcomes

Primary

MeasureTime frame
National Institute of Health stroke scale;Barthel Index;Modified Rankin Scale;Image results (CT, CTA, CTP or MRI );Safty;

Countries

China

Contacts

Public ContactHuisheng Chen

The General Hospital of Shenyang Military

chszh@aliyun.com+86 13352452086

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026